ESR1 Mutations in Metastatic HR+ HER2- Breast Cancer: Testing and Treatment 

These presentations offer a comprehensive review of ESR1 mutations in hormone receptor-positive (HR+) HER2-negative metastatic breast cancer, focusing on their role in breast cancer biology, patient outcomes, treatment decision-making, and clinical practice. The sessions will discuss the role of ESR1 mutations, current guidelines for ESR1 mutation testing and treatment, and the evolving treatment landscape. They will also highlight findings from major clinical trials involving patients with relapsed HR+ HER2-negative metastatic breast cancer, both with and without ESR1 mutations.

Program Content

Activities

ESR1 Mutations in Metastatic Breast Cancer
ESR1 Mutations in Metastatic HR+ HER2- Breast Cancer: Testing and Treatment-Presented by Seth Wander, MD, PhD
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 19, 2025

Expires: February 18, 2026

ESR1 Mutations in Metastatic Breast Cancer
ESR1 Mutations in Metastatic HR+ HER2- Breast Cancer: Testing and Treatment-Presented by Virginia Kaklamani, MD, DSc
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 19, 2025

Expires: February 18, 2026

ESR1 Mutations in Metastatic Breast Cancer
ESR1 Mutations in Metastatic HR+ HER2- Breast Cancer: Testing and Treatment-Presented by Aditya Bardia, MD, MPH, FASCO
Video
Congratulations: You achieved a completion on 04/09/2022

Released: February 19, 2025

Expires: February 18, 2026